Calcium, Phosphorus and Parathyroid Hormone Metabolism in Chronic Hemofiltration

2015 ◽  
pp. 77-85 ◽  
Author(s):  
A. M. Pierides ◽  
D. Giacherio ◽  
B. Schniepp ◽  
M. Burritt
Keyword(s):  
Parathyroid Hormone ◽  
Hormone Metabolism ◽  
Calcium Phosphorus

Ethnic variations in parathyroid hormone metabolism in the morbidly obese

2005 ◽  
Vol 1 (3) ◽  
pp. 270
Author(s):  
Brandon Chock ◽  
Nahid Hamoui ◽  
Gary J. Anthone ◽  
Peter F. Crookes
Keyword(s):  
Parathyroid Hormone ◽  
Morbidly Obese ◽  
Hormone Metabolism ◽  
Ethnic Variations

scholarly journals Association of vitamin D and osteocalcin levels in post-menopausal women with osteoporosis

2017 ◽  
Vol 6 (4) ◽  
pp. 1244
Author(s):  
Yogiraj Vaijanathrao Chidre ◽  
Amir Babansab Shaikh
Keyword(s):  
Vitamin D ◽  
Parathyroid Hormone ◽  
Vitamin D Deficiency ◽  
Fragility Fractures ◽  
Bone Fragility ◽  
Vitamin D Supplementation ◽  
Mineral Density ◽  
Age Related ◽  
Calcium Phosphorus ◽  
Post Menopausal

Background: Osteoporosis is a common age related problem especially in women, with a consequent increase in bone fragility and susceptibility to fracture. Apart from Calcium, another nutrient that plays an important role in the mineralization of skeleton in Vitamin D. Osteocalcin, which is produced primarily by osteoblasts during bone formation, is considered to be one of the markers for osteoporosis.Methods: 314 women above the age of 40 were included into the study. A thorough physical and clinical examination, assessment of vital parameters, anthropometry evaluation was done for all patients. Bone mineral density was calculated using central DXA osteodensitometer at lumbar spine L1-L4, hip and ultradistal radius (in some cases.). Blood samples were taken for the detection of ionized calcium, phosphorus, alkaline phosphatase, 25hydroxivitamin D (25 ODH) and serum parathyroid hormone (PTH) by chemiluminiscent assay. Bone markers such as osteocalcin were measured as required.Results: Out of the 314 women attending our OPD, 96 of them were diagnosed as having osteoporosis. 24 out of them had fragility fractures, mainly of the hip, and 82 had ostepenia. Elevated levels of calcium (8.96 mg/dl), parathyroid hormone (58.76 pg/ml) and osteocalcin (24.46 ng/ml) were observed. Vitamin D deficiency of ≤ 20 was seen in 59 (63%) of the cases, insufficient in 23 (24%) and only 12 (13%) of these women had normal Vitamin D levels.Conclusions: Osteocalcin is a promising marker for the detection of osteoporosis. There is a considerable Vitamin D deficiency among the women with osteoporosis, and it is under-treated. It is essential to provide Vitamin D supplementation to these women especially those who are at high risk for fragility fractures.

scholarly journals The effectiveness of nutritional vitamin D supplementation and selective vitamin D receptor agonists treatment on secondary hyperparathyroidism in chronic kidney diseases patients

2018 ◽  
Vol 21 (2) ◽  
pp. 12-22 ◽  
Author(s):  
Lilit V. Egshatyan ◽  
Natalya G. Mokrisheva
Keyword(s):  
Vitamin D ◽  
Parathyroid Hormone ◽  
Secondary Hyperparathyroidism ◽  
Vitamin D Receptor ◽  
Vitamin D Supplementation ◽  
Target Range ◽  
Receptor Agonists ◽  
Stage 4 ◽  
Calcium Phosphorus ◽  
Phosphorus Levels

Background: secondary hyperparathyroidism (SHPT) is an early complication of chronic kidney disease (CKD). Maintaining the level of 25(OH)D and parathyroid hormone concentrations in the target range reduce its associated complications (fractures and cardiovascular calcification). Aims: to examine the effectiveness of vitamin D supplementation and selective vitamin D receptor agonists treatment on SHPT in CKD. Material and methods: prospective observational study to evaluate the efficacy and safety of vitamin D therapy SHPT in 54 in patients with CKD. The first phase (24 weeks) – treatment of suboptimal 25-hydroxycalciferol (25(OH)D) levels. The second (16 weeks) – treatment colecalciferol-resistant SHPT by combination of cholecalciferol with paricalcitol. Blood samples were taken to assess parathyroid hormone (PTH), 25(OH)D, creatinine, calcium, phosphorus levels and calcium excretion. Results: After 8 weeks of cholecalciferol treatment all patients achieved 25(OH)D levels above 20 ng/ml, however 78% of patients still had SHPT. After 16 weeks, the decrease of PTH was achieved in all patients, but significantly only in patients with CKD 2 (19.2%, p< 0.01) and 3 (31%, p <0.05), compared with CKD 4 (17%, p >0.05). After 24 weeks of therapy, PTH normalized in all patients with CKD 2, in 15 (79%) with CKD 3 and in 9 (50%) patients with CKD 4. Cholecalciferol treatment resulted in a substantial increase in 25(OH)D levels with minimal or no impact on calcium, phosphorus levels and kidney function. After 24 weeks we initiated combination therapy (cholecalciferol and paricalcitol) for patients with colecalciferol-resistant SHPT (n=13). PTH levels decreased from 149.1±13.4 to 118.2±14.1 pg/ml at 8 weeks, and to 93.1±9.7 pg/ml (p <0.05) at 16 weeks of treatment. No significant differences in serum calcium, phosphorus or urinary calcium levels. Normalization of PTH was achieved in all patients with CKD 3 and in 8 patients with stage 4. One patient with CKD 4 needed an increase in paricalcitol dose. Conclusion: Cholecalciferol can be used in correcting vitamin D deficiency in patients with all stages of CKD, however, its effectiveness in reducing PTH in stage 4 is limited. Selective analogs, such as paricalcitol, were well-tolerated and effectively decreased PTH levels.

A HORMONAL ASSESSMENT OF BOVINE PARTURIENT PARESIS: EVIDENCE FOR A ROLE OF OESTROGEN

1981 ◽  
Vol 88 (2) ◽  
pp. 161-171 ◽  
Author(s):  
B. W. HOLLIS ◽  
H. H. DRAPER ◽  
J. H. BURTON ◽  
R. J. ETCHES
Keyword(s):  
Parathyroid Hormone ◽  
Bone Resorption ◽  
Plasma Levels ◽  
Post Partum ◽  
Comparative Assessment ◽  
Hormonal Control ◽  
Elevated Plasma ◽  
Calcium Phosphorus ◽  
Parturient Paresis

A comparative assessment was made of the hormonal control of calcium homeostasis in eight dairy cows which developed parturient paresis and in seven normal animals from the same herd. Plasma levels of calcium, phosphorus, magnesium, free hydroxyproline, 25-hydroxycholecalciferol (25-OHD), 1,25-dihydroxycholecalciferol (1,25-(OH)2D), parathyroid hormone, calcitonin, prolactin and oestrogen were monitored from 30 days prepartum to 15 days post partum. Prepartum levels of plasma calcium, hydroxyproline and calcitonin were depressed in the paretic animals, and plasma levels of phosphorus and oestrogen were elevated. Plasma levels of 25-OHD remained stable in both groups, whereas levels of 1,25-(OH)2D, parathyroid hormone and prolactin rose sharply at parturition. Plasma hydroxyproline, an index of bone resorption, began to rise 2 days prepartum in the control cows but not until 2 days post partum in the paretic cows. The data indicate that bone resorption was inhibited in the paretic group at the onset of lactation, and that a decreased capacity for bone resorption is a major factor in the susceptibility of some cows to this disease. The failure of the paretic animals to resorb bone was not associated with an inability to synthesize the calcium-mobilizing hormones parathyroid hormone or 1,25-(OH)2D, or to regulate the production of calcitonin. However, hypocalcaemia in the affected animals was associated with a significantly higher plasma level of oestrogen (a known inhibitor of bone resorption) in the immediate prepartum period. Following parturition, plasma levels of oestrogen fell rapidly and active bone resorption ensued in the paretic animals.

scholarly journals Serum Sulphate Levels in Hemodialysis Patients

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
Ibrahim Yildirim ◽  
Ender Hur ◽  
Kemal Magden ◽  
Sevil İlikhan ◽  
Hüseyin Engin ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Serum Levels ◽  
Hemodialysis Patients ◽  
Free Form ◽  
Control Group ◽  
Dialysis Patients ◽  
Sulphur Compounds ◽  
Adequate Knowledge ◽  
Inorganic Sulphate ◽  
Calcium Phosphorus

Objective. Sulphur, similar to phosphorus, is easily attached to organic compounds. The inadequate elimination of sulphate may cause high sulphate concentrations in hemodialysis (HD) patients because sulphate is low in free form in plasma. Although we are well aware of the accumulation of phosphorus in chronic dialysis patients, we do not have an adequate knowledge database about the sulphur compounds. This study was designed to determine the level of sulphate in hemodialysis patients. Materials and Methods. Ninety-four prevalent HD patients and 33 patients without renal failure were included in the study. The serum inorganic sulphate levels were measured by turbidimetric technique. Moreover, the serum level of urea, creatinine, albumin, calcium, phosphorus, and parathyroid hormone concentrations was simultaneously recorded. Results. Mean levels of plasma sulphate were significantly higher (0.56 ± 0.17 mM vs 0.31 ± 0.13 mM, p<0.001) in HD patients. Serum sulphate level correlated with patient’s age, serum albumin, serum BUN and creatinine, and serum phosphorus level in HD patients. Serum sulphate levels were not associated with serum parathyroid hormone levels. Conclusion. Serum sulphate levels were approximately twofold higher in HD patients than in the normal control group. Inorganic sulphate does not seem to accumulate in long-term dialysis patients, and mild increased serum levels of sulphate has no poor clinical outcome in these patients.

scholarly journals Parathyroid Hormone Fragments: New Targets for the Diagnosis and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder

2018 ◽  
Vol 2018 ◽  
pp. 1-14 ◽  
Author(s):  
Huimin Chen ◽  
Xiaxia Han ◽  
Ying Cui ◽  
Yangfan Ye ◽  
Yogendranath Purrunsing ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Parathyroid Hormone ◽  
Kidney Disease ◽  
Vital Role ◽  
Diagnosis And Treatment ◽  
Mineral And Bone Disorder ◽  
Bone Disorder ◽  
Calcium Phosphorus ◽  
Further Development ◽  
Made In

As a common disorder, chronic kidney disease (CKD) poses a great threat to human health. Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a complication of CKD characterized by disturbances in the levels of calcium, phosphorus, parathyroid hormone (PTH), and vitamin D; abnormal bone formation affecting the mineralization and linear growth of bone; and vascular and soft tissue calcification. PTH reflects the function of the parathyroid gland and also takes part in the metabolism of minerals. The accurate measurement of PTH plays a vital role in the clinical diagnosis, treatment, and prognosis of patients with secondary hyperparathyroidism (SHPT). Previous studies have shown that there are different fragments of PTH in the body’s circulation, causing antagonistic effects on bone and the kidney. Here we review the metabolism of PTH fragments; the progress being made in PTH measurement assays; the effects of PTH fragments on bone, kidney, and the cardiovascular system in CKD; and the predictive value of PTH measurement in assessing the effectiveness of parathyroidectomy (PTX). We hope that this review will help to clarify the value of accurate PTH measurements in CKD-MBD and promote the further development of multidisciplinary diagnosis and treatment.

scholarly journals Role of Jumpstart Nutrition®, a Dietary Supplement, to Ameliorate Calcium-to-Phosphorus Ratio and Parathyroid Hormone of Patients with Osteoarthritis

2019 ◽  
Vol 7 (12) ◽  
pp. 105
Author(s):  
Apurba Ganguly
Keyword(s):  
Parathyroid Hormone ◽  
Functional Capacity ◽  
Coenzyme Q10 ◽  
Rescue Medication ◽  
Vitamin K2 ◽  
Karnofsky Performance Scale ◽  
Supplement Group ◽  
Radiological Images ◽  
Calcium Phosphorus ◽  
25 Hydroxy Vitamin D

The aim of this study was to use Jumpstart Nutrition® bone supplementing combination with vitamin-K2 and coenzyme-Q10 characterized by an innovative delivery system that improves bioavailability of calcium-to-phosphorus ratio (CPR) and parathyroid hormone (PTH) in the management of osteoarthritis (OA). This eight-week registry included 108 patients treated for symptomatic OA confirmed with radiological images. On top of that, 63 patients used Jumpstart Nutrition® supplement, mainly prepared with calcium, phosphorus, coenzyme-Q10, vitamin-K2, vitamin-D2, vitamin-C, folic acid, curcumin and boswellic acids. Rescue medication was also recommended. Patients’ pain and functional capacity through outcome measures—knee-injury osteoarthritis outcome scale (KOOS) and Karnofsky performance scale (KPS), biomarkers such as levels of CPR, PTH and 25-hydroxy-vitamin-D were evaluated for the groups with and without supplement using appropriate kits. After eight weeks, the levels of CPR and PTH were all significantly improved (p < 0.001), fewer subjects had to use rescue medication (p < 0.05) and variation of pain and functional capacity under KOOS and KPS (p < 0.05) of the patients in the supplement group compared to controls. This registry study indicates that Jumpstart Nutrition® can be used safely for effective management of OA patients for the amelioration of CPR, PTH and functional activities confirmed with biomarkers and radiological images correlated with the Kellgren-Lawrance scale.

Sign in / Sign up

Export Citation Format

Share Document